NeoGenomics commences $275M convertible note offering due 2032

NEOGENOMICS INC

Offering $275M aggregate principal amount of convertible senior notes due 2032, with option for additional $41.25M.
Notes offered to qualified institutional buyers under Rule 144A; interest rate and conversion rate set at pricing.
Proceeds used to repurchase a portion of existing 0.25% convertible notes due 2028 and up to $25M of common stock.
Company to enter capped call transactions to reduce potential dilution upon conversion.
The offering is contingent on market conditions and not registered under the Securities Act.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.